- Home
- NKTR
NKTR
Nektar Therapeutics
as 06-20-2025 4:00pm EST
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 125.5M | IPO Year: | 1994 |
| Target Price: | $73.75 | AVG Volume (30 days): | 348.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.48 - $22.79 | Next Earning Date: | 08-07-2025 |
| Revenue: | $87,248,000 | Revenue Growth: | -3.24% |
| Revenue Growth (this year): | -55.41% | Revenue Growth (next year): | -7.23% |
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | NKTR | Chief Legal Officer | May 19 '25 | Sell | $0.67 | 9,996 | $6,697.32 | 314,296 | |
| ROBIN HOWARD W | NKTR | President & CEO | May 19 '25 | Sell | $0.67 | 23,208 | $15,549.36 | 1,063,693 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | May 19 '25 | Sell | $0.67 | 10,712 | $7,177.04 | 305,892 |
Latest Nektar Therapeutics News
NKTR Breaking Stock News: Dive into NKTR Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
PR Newswire
a month ago
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Simply Wall St.
a month ago
Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook
Simply Wall St.
a month ago
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations
Thomson Reuters StreetEvents
a month ago
Q1 2025 Nektar Therapeutics Earnings Call
Zacks
a month ago
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
GuruFocus.com
a month ago
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ...
Zacks
a month ago
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
Compare NKTR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.